WRN Peptide
€100.00
In stock
SKU
350527
Protein Family: Enzymes
Pathway and Disease: Cancers, Metabolic Disorders, Replication and Repair
Alternate Names: Werner syndrome ATP-dependent helicase; WRN; RECQ3; RECQL2
Accession No.: Q14191, NP_000544
Description:
Werner syndrome ATP-dependent helicase (WRN) is essential for the formation of DNA replication focal centers and associates with foci elements generating binding sites for RPA. Defects in WRN are a cause of Werner syndrome, a multiple age-related disorders, including atherosclerosis, cancer, diabetes and osteoporosis.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 2045.3 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200165 is selected from a sequence within the N-term region of human WRN. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C94H141N21O28S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Metabolic Disorders, Replication and Repair
Alternate Names: Werner syndrome ATP-dependent helicase; WRN; RECQ3; RECQL2
Accession No.: Q14191, NP_000544
Description:
Werner syndrome ATP-dependent helicase (WRN) is essential for the formation of DNA replication focal centers and associates with foci elements generating binding sites for RPA. Defects in WRN are a cause of Werner syndrome, a multiple age-related disorders, including atherosclerosis, cancer, diabetes and osteoporosis.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 2045.3 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200165 is selected from a sequence within the N-term region of human WRN. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C94H141N21O28S1
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review